These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27545964)

  • 1. Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice.
    Mulder P; Morrison MC; Verschuren L; Liang W; van Bockel JH; Kooistra T; Wielinga PY; Kleemann R
    Sci Rep; 2016 Aug; 6():31542. PubMed ID: 27545964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity.
    Mulder P; Morrison MC; Wielinga PY; van Duyvenvoorde W; Kooistra T; Kleemann R
    Int J Obes (Lond); 2016 Apr; 40(4):675-84. PubMed ID: 26499443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.Leiden mice.
    Schoemaker MH; Kleemann R; Morrison MC; Verheij J; Salic K; van Tol EAF; Kooistra T; Wielinga PY
    PLoS One; 2017; 12(7):e0180648. PubMed ID: 28678821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipose tissue-related proteins locally associated with resolution of inflammation in obese mice.
    Jilkova ZM; Hensler M; Medrikova D; Janovska P; Horakova O; Rossmeisl M; Flachs P; Sell H; Eckel J; Kopecky J
    Int J Obes (Lond); 2014 Feb; 38(2):216-23. PubMed ID: 23756677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
    van der Veen JN; Lingrell S; Gao X; Quiroga AD; Takawale A; Armstrong EA; Yager JY; Kassiri Z; Lehner R; Vance DE; Jacobs RL
    Am J Physiol Gastrointest Liver Physiol; 2016 Apr; 310(7):G526-38. PubMed ID: 26797396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity.
    Lee SM; Muratalla J; Diaz-Ruiz A; Remon-Ruiz P; McCann M; Liew CW; Kineman RD; Cordoba-Chacon J
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34417811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
    Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
    PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk.
    van den Hoek AM; de Jong JCBC; Worms N; van Nieuwkoop A; Voskuilen M; Menke AL; Lek S; Caspers MPM; Verschuren L; Kleemann R
    Metabolism; 2021 Nov; 124():154873. PubMed ID: 34478753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
    Falkevall A; Mehlem A; Folestad E; Ning FC; Osorio-Conles Ó; Radmann R; de Hollanda A; Wright SD; Scotney P; Nash A; Eriksson U
    J Hepatol; 2023 May; 78(5):901-913. PubMed ID: 36717026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adipose tissue-liver crosstalk during pathologic changes caused by vinyl chloride metabolites in mice.
    Kaelin BR; McKenzie CM; Hempel KW; Lang AL; Arteel GE; Beier JI
    Toxicol Appl Pharmacol; 2020 Jul; 399():115068. PubMed ID: 32445754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice.
    Sun X; Tang Y; Tan X; Li Q; Zhong W; Sun X; Jia W; McClain CJ; Zhou Z
    Am J Physiol Gastrointest Liver Physiol; 2012 Mar; 302(5):G548-57. PubMed ID: 22173916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity.
    Di Mascolo D; J Lyon C; Aryal S; Ramirez MR; Wang J; Candeloro P; Guindani M; Hsueh WA; Decuzzi P
    J Control Release; 2013 Sep; 170(3):460-8. PubMed ID: 23791978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased lipogenesis in white adipose tissue contributes to the resistance to high fat diet-induced obesity in phosphatidylethanolamine N-methyltransferase-deficient mice.
    Gao X; van der Veen JN; Hermansson M; Ordoñez M; Gomez-Muñoz A; Vance DE; Jacobs RL
    Biochim Biophys Acta; 2015 Feb; 1851(2):152-62. PubMed ID: 25463480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucoraphanin Ameliorates Obesity and Insulin Resistance Through Adipose Tissue Browning and Reduction of Metabolic Endotoxemia in Mice.
    Nagata N; Xu L; Kohno S; Ushida Y; Aoki Y; Umeda R; Fuke N; Zhuge F; Ni Y; Nagashimada M; Takahashi C; Suganuma H; Kaneko S; Ota T
    Diabetes; 2017 May; 66(5):1222-1236. PubMed ID: 28209760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation.
    Pan ZG; An XS
    Biochem Biophys Res Commun; 2018 Apr; 498(3):416-423. PubMed ID: 29454967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
    Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
    Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine.
    Mueller AM; Kleemann R; Gart E; van Duyvenvoorde W; Verschuren L; Caspers M; Menke A; Krömmelbein N; Salic K; Burmeister Y; Seilheimer B; Morrison MC
    Front Endocrinol (Lausanne); 2021; 12():601160. PubMed ID: 33815271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis.
    Mulder P; van den Hoek AM; Kleemann R
    PLoS One; 2017; 12(1):e0169740. PubMed ID: 28076416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
    Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
    Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Outcomes of Rosiglitazone Treatment on Fatty Liver.
    Gao M; Ma Y; Alsaggar M; Liu D
    AAPS J; 2016 Jul; 18(4):1023-31. PubMed ID: 27125895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.